Sugi Predict

Sugi Predict / Compounds / SCHEMBL14025793

SCHEMBL14025793

SCHEMBL14025793

C[C@@]12C(=O)N(O)C(=O)[C@]1(C)[C@H]1CC[C@@H]2O1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 5/20 0.55
▸ TP53 P04637 4/20 0.55
▸ CYP3A4 P08684 4/20 0.55
▸ HIF1A Q16665 3/20 0.55
▸ LMNA P02545 3/20 0.55
▸ SMN1; SMN2 Q16637 3/20 0.55
▸ NPC1 O15118 3/20 0.55
▸ RAB9A P51151 3/20 0.55
▸ CYP1A2 P05177 2/20 0.55
▸ NFKB1 P19838 2/20 0.55
▸ THPO P40225 2/20 0.55
▸ GMNN O75496 2/20 0.55
▸ MTOR P42345 2/20 0.55
▸ BLM P54132 2/20 0.55
▸ PMP22 Q01453 2/20 0.55
▸ KDM4E B2RXH2 2/20 0.55
▸ PPM1B O75688 1/20 0.55
▸ PTPN1 P18031 1/20 0.55
▸ PPP1CC P36873 1/20 0.55
▸ TFPI2 P48307 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17663719 1.00 MAPK1 (0.55) MAPK1TP53CYP3A4HIF1ALMNA
SCHEMBL14025795 0.81 MAPK1 (0.57) MAPK1TP53CYP3A4HIF1ALMNA
SCHEMBL17663718 0.76 MAPK1 (0.52) MAPK1TP53CYP3A4HIF1ALMNA
SCHEMBL14045841 0.73 MAPK1 (0.48) MAPK1TP53CYP3A4HIF1ALMNA
Cantharidin SCHEMBL28433736 0.72 MAPK1 (0.91) MAPK1TP53CYP3A4HIF1ALMNA
SCHEMBL14025794 0.72 MAPK1 (0.47) MAPK1TP53CYP3A4HIF1ALMNA
Cantharidin SCHEMBL14120808 0.71 MAPK1 (1.00) MAPK1TP53CYP3A4HIF1ALMNA
Cantharidin SCHEMBL152262 0.71 MAPK1 (1.00) MAPK1TP53CYP3A4HIF1ALMNA
Cantharidin SCHEMBL1805181 0.71 MAPK1 (1.00) MAPK1TP53CYP3A4HIF1ALMNA
Cantharidin SCHEMBL152261 0.71 MAPK1 (1.00) MAPK1TP53CYP3A4HIF1ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150224083-A1 Cancer Therapy With Cantharidin And Cantharidin Analogs STEMLINE THERAPEUTICS INC (US) 2015-08-13 — — US disclosed
US-20150224083-A1 Cancer Therapy With Cantharidin And Cantharidin Analogs STEMLINE THERAPEUTICS INC (US) 2015-08-13 — — US disclosed
US-20080267947-A1 Cancer therapy with cantharidin and cantharidin analogs STEMLINE THERAPEUTICS, INC. 2008-10-30 — — US disclosed
US-20080267947-A1 Cancer therapy with cantharidin and cantharidin analogs STEMLINE THERAPEUTICS, INC. 2008-10-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150224083-A1 Cancer Therapy With Cantharidin And Cantharidin Analogs ASAH2, TYR, CD47 MAPK1 3389/4885TP53 38/4885CYP3A4 3756/4885
US-20080267947-A1 Cancer therapy with cantharidin and cantharidin analogs ASAH2, TYR, CD47 MAPK1 3389/4885TP53 38/4885CYP3A4 3756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.